Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26
Taysha Gene Therapies (TSHA), a clinical-stage biotechnology company specializing in AAV-based gene therapies for CNS disorders, has announced it will release its full-year 2024 financial results and host a corporate update conference call on February 26, 2025. The event will take place at 8:30 AM Eastern Time.
The company has provided both domestic and international dial-in numbers for interested parties to participate in the conference call, which will also be accessible via webcast through the company's investor relations website.
Taysha Gene Therapies (TSHA), un'azienda biotecnologica in fase clinica specializzata in terapie geniche basate su AAV per disturbi del sistema nervoso centrale, ha annunciato che rilascerà i risultati finanziari dell'intero anno 2024 e ospiterà una conference call di aggiornamento aziendale il 26 febbraio 2025. L'evento si svolgerà alle 8:30 AM ora orientale.
L'azienda ha fornito numeri di accesso sia nazionali che internazionali per le parti interessate a partecipare alla conference call, che sarà anche accessibile tramite webcast attraverso il sito web delle relazioni con gli investitori dell'azienda.
Taysha Gene Therapies (TSHA), una empresa biotecnológica en etapa clínica especializada en terapias génicas basadas en AAV para trastornos del sistema nervioso central, ha anunciado que publicará sus resultados financieros del año completo 2024 y llevará a cabo una conferencia de actualización corporativa el 26 de febrero de 2025. El evento se llevará a cabo a las 8:30 AM hora del Este.
La empresa ha proporcionado números de acceso tanto nacionales como internacionales para que las partes interesadas participen en la conferencia, que también estará disponible a través de webcast en el sitio web de relaciones con inversores de la empresa.
Taysha Gene Therapies (TSHA)는 CNS 질환을 위한 AAV 기반 유전자 치료를 전문으로 하는 임상 단계의 생명공학 회사로, 2025년 2월 26일에 2024년 전체 연도 재무 결과를 발표하고 기업 업데이트 컨퍼런스 콜을 개최한다고 발표했습니다. 이 행사는 동부 표준시 기준으로 오전 8시 30분에 진행됩니다.
회사는 컨퍼런스 콜에 참여하고자 하는 이해관계자들을 위해 국내 및 국제 전화 접속 번호를 제공하였으며, 회사의 투자자 관계 웹사이트를 통해 웹캐스트로도 접근 가능합니다.
Taysha Gene Therapies (TSHA), une entreprise de biotechnologie en phase clinique spécialisée dans les thérapies géniques basées sur AAV pour les troubles du système nerveux central, a annoncé qu'elle publiera ses résultats financiers de l'année 2024 et organisera une conférence de mise à jour d'entreprise le 26 février 2025. L'événement se déroulera à 8h30, heure de l'Est.
L'entreprise a fourni des numéros d'accès nationaux et internationaux pour les parties intéressées souhaitant participer à la conférence, qui sera également accessible par webdiffusion via le site web des relations avec les investisseurs de l'entreprise.
Taysha Gene Therapies (TSHA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf AAV-basierte Gentherapien für Erkrankungen des zentralen Nervensystems spezialisiert hat, hat angekündigt, dass es seine Finanzberichte für das gesamte Jahr 2024 veröffentlichen und am 26. Februar 2025 eine Unternehmensupdate-Konferenzschaltung durchführen wird. Die Veranstaltung findet um 8:30 Uhr Eastern Time statt.
Das Unternehmen hat sowohl nationale als auch internationale Einwahlnummern bereitgestellt, damit interessierte Parteien an der Konferenzschaltung teilnehmen können, die auch über einen Webcast auf der Website der Investor Relations des Unternehmens zugänglich sein wird.
- None.
- None.
DALLAS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2024, and host a corporate update conference call and webcast on Wednesday, February 26, 2025, at 8:30 AM Eastern Time.
Conference Call Details
Wednesday, February 26, at 8:30 AM Eastern Time / 7:30 AM Central Time
Toll Free: 877-407-0792
International: 201-689-8263
Conference ID: 13751800
Webcast: https://ir.tayshagtx.com/news-events/events-presentations
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.
Company Contact:
Hayleigh Collins
Director, Head of Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
Media Contact:
Carolyn Hawley
Inizio Evoke
carolyn.hawley@inizioevoke.com
FAQ
When will Taysha Gene Therapies (TSHA) release its 2024 full-year financial results?
What time is TSHA's Q4 2024 earnings call scheduled for?
How can investors access TSHA's February 26 earnings call?
What is the conference ID for TSHA's 2024 full-year earnings call?
